BChE-IN-14 (compound 19c) can restore cognitive impairment in vivo that can be used in the Alzheimer’s disease research. BChE-IN-14 has primary cell safety and good blood brain barrier permeability. BChE-IN-14 is a selective inhibitor of butyrylcholinesterase (BChE) with IC50 values of 0.011 μM and 0.23 μM for hBChE and eqBChE, respectively [1].

BChE-IN-14 (0.0001-100 μM) inhibits eqBChE from house serum and hBChE with IC 50 s of 0.23 and 0.011 μM, respectively [1].

BChE-IN-14 (15 mg/kg; p.o. for Aβ 1-42 injection days 3-8) affects memory and cognitive function in AD mice model [1]. Animal Model: ICR mice with oligomerized Aβ 1-42 peptide injection [1] Dosage: 15 mg/kg Administration: Oral gavage; 15 mg/kg for Aβ 1-42 injection days 3-8 Result: Improved memory and cognitive function in vivo and showed a shorter latency than donepezil.